Product Description
Reference Standards &Impurity
AI Product Description
*The following content is generated by AI and is for reference only.
Lercanidipine is a third-generation dihydropyridine calcium channel blocker primarily utilized in the management of hypertension. Its chemical identity is defined by the molecular formula C32H46N2O8 and the CAS Registry Number 107695-13-4. Structurally, this compound features a unique bis(alkoxy)phenyl moiety attached to a dihydropyridine core, which significantly enhances its lipophilicity compared to earlier generations of similar drugs like nifedipine or amlodipine. This high lipid solubility allows for rapid absorption from the gastrointestinal tract and extensive tissue distribution, yet it minimizes accumulation in vascular smooth muscle cells relative to plasma, contributing to a distinct pharmacokinetic profile.
The primary therapeutic application of Lercanidipine is the treatment of essential hypertension. By selectively blocking L-type voltage-gated calcium channels in vascular smooth muscle, it induces potent vasodilation of peripheral arteries, thereby reducing systemic vascular resistance and lowering blood pressure without causing significant reflex tachycardia. A notable clinical advantage of this agent is its long duration of action, typically allowing for once-daily dosing, which improves patient compliance. Furthermore, due to its high selectivity for vascular over cardiac tissue, it generally exhibits a lower incidence of adverse effects such as peripheral edema, flushing, and palpitations when compared to non-selective dihydropyridines. The drug is often prescribed as monotherapy or in combination with other antihypertensive agents, including ACE inhibitors or diuretics, to achieve optimal blood pressure control. It is particularly beneficial for elderly patients and those with isolated systolic hypertension. While generally well-tolerated, common side effects may include mild dizziness or headache. Overall, Lercanidipine represents a sophisticated evolution in antihypertensive therapy, offering effective blood pressure reduction with an improved safety and tolerability profile suitable for long-term cardiovascular management.